Faculty of Health and Life Sciences, Department of Public Health and Sport Sciences, University of Exeter, Exeter EX1 2LU, UK.
Nutrients. 2024 Jul 17;16(14):2291. doi: 10.3390/nu16142291.
Adipose tissue and skeletal muscle dysfunction play a central role in cardiometabolic morbidity. Ashwagandha and Andrographis are purported to have anti-inflammatory and antioxidant activity, but this is based on exposure of cells to the parent compounds ignoring phytochemical absorption and metabolism. We explored the anti-inflammatory/antioxidant effects of ashwagandha and Andrographis in ex vivo human models of skeletal muscle and adipose tissue. Healthy participants supplemented with 2000 mg/day Andrographis (n = 10) or 1100 mg/day ashwagandha (n = 10) for 28 days. Sera collected pre (D0) and post (D28) supplementation were pooled by timepoint and added to adipose explant (AT) and primary human myotube (SKMC) culture media (15% /) for treatment. A Taqman panel of 56 genes was used to quantify these. In AT, treatment with ashwagandha sera decreased the expression of genes involved in antioxidant defence and inflammatory response (, , , , , , , , ; geometric 95% CI for fold change > 1) and altered the expression of genes involved in fatty acid metabolism. In SKMC, ashwagandha sera altered and expression. Andrographis sera decreased and expression in AT. This physiologically relevant in vitro screening characterises the effects of ashwagandha in AT to guide future clinical trials.
脂肪组织和骨骼肌功能障碍在心脏代谢发病率中起着核心作用。 Ashwagandha 和穿心莲被认为具有抗炎和抗氧化活性,但这是基于细胞暴露于母体化合物而忽略植物化学物质吸收和代谢的基础上。我们在体外人类骨骼肌和脂肪组织模型中探索了 Ashwagandha 和穿心莲的抗炎/抗氧化作用。健康参与者每天补充 2000 毫克穿心莲(n = 10)或 1100 毫克 Ashwagandha(n = 10)28 天。在补充前(D0)和补充后(D28)收集的血清按时间点汇集,并添加到脂肪组织外植体(AT)和原代人类肌管(SKMC)培养基中(15% /)进行处理。使用 Taqman 面板 56 个基因来定量这些基因。在 AT 中, Ashwagandha 血清处理降低了抗氧化防御和炎症反应相关基因的表达(,,,,,,,,;几何 95%置信区间的倍数变化> 1),并改变了脂肪酸代谢相关基因的表达。在 SKMC 中, Ashwagandha 血清改变了和的表达。穿心莲血清降低了 AT 中的和表达。这种生理相关的体外筛选特征描述了 Ashwagandha 在 AT 中的作用,为未来的临床试验提供了指导。